Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 199.33
NLNK's Cash to Debt is ranked higher than
55% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. NLNK: 199.33 )
Ranked among companies with meaningful Cash to Debt only.
NLNK' s Cash to Debt Range Over the Past 10 Years
Min: 0.79  Med: 44.90 Max: N/A
Current: 199.33
Equity to Asset 0.91
NLNK's Equity to Asset is ranked higher than
85% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NLNK: 0.91 )
Ranked among companies with meaningful Equity to Asset only.
NLNK' s Equity to Asset Range Over the Past 10 Years
Min: -5.11  Med: 0.78 Max: 0.93
Current: 0.91
-5.11
0.93
Interest Coverage 1228.80
NLNK's Interest Coverage is ranked lower than
75% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NLNK: 1228.80 )
Ranked among companies with meaningful Interest Coverage only.
NLNK' s Interest Coverage Range Over the Past 10 Years
Min: 4522.04  Med: 4522.04 Max: 4522.04
Current: 1228.8
F-Score: 7
Z-Score: 25.32
M-Score: 52.28
WACC vs ROIC
14.90%
625.57%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 56.61
NLNK's Operating margin (%) is ranked higher than
96% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. NLNK: 56.61 )
Ranked among companies with meaningful Operating margin (%) only.
NLNK' s Operating margin (%) Range Over the Past 10 Years
Min: -2849.13  Med: -1108.03 Max: 68.12
Current: 56.61
-2849.13
68.12
Net-margin (%) 46.96
NLNK's Net-margin (%) is ranked higher than
95% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. NLNK: 46.96 )
Ranked among companies with meaningful Net-margin (%) only.
NLNK' s Net-margin (%) Range Over the Past 10 Years
Min: -2852.7  Med: -1067.88 Max: 59.6
Current: 46.96
-2852.7
59.6
ROE (%) 57.46
NLNK's ROE (%) is ranked higher than
99% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. NLNK: 57.46 )
Ranked among companies with meaningful ROE (%) only.
NLNK' s ROE (%) Range Over the Past 10 Years
Min: -85.27  Med: -81.78 Max: 78.49
Current: 57.46
-85.27
78.49
ROA (%) 51.30
NLNK's ROA (%) is ranked higher than
99% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. NLNK: 51.30 )
Ranked among companies with meaningful ROA (%) only.
NLNK' s ROA (%) Range Over the Past 10 Years
Min: -75.86  Med: -59.98 Max: 66.66
Current: 51.3
-75.86
66.66
ROC (Joel Greenblatt) (%) 543.16
NLNK's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. NLNK: 543.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NLNK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -709.08  Med: -369.45 Max: 799.97
Current: 543.16
-709.08
799.97
Revenue Growth (3Y)(%) 161.80
NLNK's Revenue Growth (3Y)(%) is ranked higher than
99% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NLNK: 161.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NLNK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -17.80 Max: 161.8
Current: 161.8
0
161.8
» NLNK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

NLNK Guru Trades in Q1 2015

Paul Tudor Jones 5,380 sh (New)
Joel Greenblatt 838,221 sh (New)
First Eagle Investment 1,430,700 sh (+1.73%)
First Eagle Investment 10,959 sh (unchged)
» More
Q2 2015

NLNK Guru Trades in Q2 2015

Joel Greenblatt 1,244,856 sh (+48.51%)
First Eagle Investment 1,719,600 sh (+20.19%)
Paul Tudor Jones 5,700 sh (+5.95%)
First Eagle Investment 7,597 sh (unchged)
» More
Q3 2015

NLNK Guru Trades in Q3 2015

Jim Simons 158,073 sh (New)
First Eagle Investment 1,876,600 sh (+9.13%)
First Eagle Investment 9,971 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
» More
Q4 2015

NLNK Guru Trades in Q4 2015

First Eagle Investment 7,770 sh (unchged)
First Eagle Investment 1,793,200 sh (-4.44%)
Jim Simons 56,921 sh (-63.99%)
» More
» Details

Insider Trades

Latest Guru Trades with NLNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 8.68
NLNK's P/E(ttm) is ranked higher than
88% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 26.73 vs. NLNK: 8.68 )
Ranked among companies with meaningful P/E(ttm) only.
NLNK' s P/E(ttm) Range Over the Past 10 Years
Min: 8.48  Med: 16.44 Max: 22.35
Current: 8.68
8.48
22.35
Forward P/E 15.17
NLNK's Forward P/E is ranked higher than
56% of the 342 Companies
in the Global Biotechnology industry.

( Industry Median: 16.21 vs. NLNK: 15.17 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 8.68
NLNK's PE(NRI) is ranked higher than
89% of the 271 Companies
in the Global Biotechnology industry.

( Industry Median: 31.00 vs. NLNK: 8.68 )
Ranked among companies with meaningful PE(NRI) only.
NLNK' s PE(NRI) Range Over the Past 10 Years
Min: 8.48  Med: 16.42 Max: 22.32
Current: 8.68
8.48
22.32
P/B 2.91
NLNK's P/B is ranked lower than
57% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. NLNK: 2.91 )
Ranked among companies with meaningful P/B only.
NLNK' s P/B Range Over the Past 10 Years
Min: 2.83  Med: 7.55 Max: 21.14
Current: 2.91
2.83
21.14
P/S 2.90
NLNK's P/S is ranked higher than
82% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 9.03 vs. NLNK: 2.90 )
Ranked among companies with meaningful P/S only.
NLNK' s P/S Range Over the Past 10 Years
Min: 2.81  Med: 200.14 Max: 1162.5
Current: 2.9
2.81
1162.5
PFCF 8.31
NLNK's PFCF is ranked higher than
87% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 30.10 vs. NLNK: 8.31 )
Ranked among companies with meaningful PFCF only.
NLNK' s PFCF Range Over the Past 10 Years
Min: 8.11  Med: 17.06 Max: 22.15
Current: 8.31
8.11
22.15
POCF 7.83
NLNK's POCF is ranked higher than
86% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 27.83 vs. NLNK: 7.83 )
Ranked among companies with meaningful POCF only.
NLNK' s POCF Range Over the Past 10 Years
Min: 7.63  Med: 16.47 Max: 21.38
Current: 7.83
7.63
21.38
EV-to-EBIT 3.16
NLNK's EV-to-EBIT is ranked higher than
82% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 18.07 vs. NLNK: 3.16 )
Ranked among companies with meaningful EV-to-EBIT only.
NLNK' s EV-to-EBIT Range Over the Past 10 Years
Min: -36.9  Med: -10.70 Max: 13.5
Current: 3.16
-36.9
13.5
EV-to-EBITDA 3.13
NLNK's EV-to-EBITDA is ranked higher than
83% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 15.20 vs. NLNK: 3.13 )
Ranked among companies with meaningful EV-to-EBITDA only.
NLNK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -38  Med: -11.00 Max: 13.4
Current: 3.13
-38
13.4
Current Ratio 19.37
NLNK's Current Ratio is ranked higher than
89% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. NLNK: 19.37 )
Ranked among companies with meaningful Current Ratio only.
NLNK' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 10.88 Max: 25.95
Current: 19.37
0.97
25.95
Quick Ratio 19.37
NLNK's Quick Ratio is ranked higher than
89% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. NLNK: 19.37 )
Ranked among companies with meaningful Quick Ratio only.
NLNK' s Quick Ratio Range Over the Past 10 Years
Min: 0.97  Med: 10.88 Max: 25.95
Current: 19.37
0.97
25.95
Days Sales Outstanding 23.90
NLNK's Days Sales Outstanding is ranked higher than
81% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. NLNK: 23.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
NLNK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.89  Med: 159.67 Max: 617.06
Current: 23.9
40.89
617.06

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.41
NLNK's Price/Net Cash is ranked higher than
67% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: 5.67 vs. NLNK: 3.41 )
Ranked among companies with meaningful Price/Net Cash only.
NLNK' s Price/Net Cash Range Over the Past 10 Years
Min: 5.21  Med: 10.99 Max: 29.76
Current: 3.41
5.21
29.76
Price/Net Current Asset Value 3.06
NLNK's Price/Net Current Asset Value is ranked higher than
68% of the 883 Companies
in the Global Biotechnology industry.

( Industry Median: 5.05 vs. NLNK: 3.06 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NLNK' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.66  Med: 9.97 Max: 21.93
Current: 3.06
4.66
21.93
Price/Tangible Book 2.92
NLNK's Price/Tangible Book is ranked higher than
62% of the 1034 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. NLNK: 2.92 )
Ranked among companies with meaningful Price/Tangible Book only.
NLNK' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.93  Med: 8.90 Max: 14.71
Current: 2.92
3.93
14.71
Price/Projected FCF 3.57
NLNK's Price/Projected FCF is ranked lower than
55% of the 273 Companies
in the Global Biotechnology industry.

( Industry Median: 2.91 vs. NLNK: 3.57 )
Ranked among companies with meaningful Price/Projected FCF only.
NLNK' s Price/Projected FCF Range Over the Past 10 Years
Min: 6.07  Med: 6.58 Max: 7.09
Current: 3.57
6.07
7.09
Price/Median PS Value 0.02
NLNK's Price/Median PS Value is ranked higher than
100% of the 846 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. NLNK: 0.02 )
Ranked among companies with meaningful Price/Median PS Value only.
NLNK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.03  Med: 0.97 Max: 3.5
Current: 0.02
0.03
3.5
Price/Graham Number 1.06
NLNK's Price/Graham Number is ranked higher than
72% of the 431 Companies
in the Global Biotechnology industry.

( Industry Median: 2.37 vs. NLNK: 1.06 )
Ranked among companies with meaningful Price/Graham Number only.
NLNK' s Price/Graham Number Range Over the Past 10 Years
Min: 1.81  Med: 2.03 Max: 2.35
Current: 1.06
1.81
2.35
Earnings Yield (Greenblatt) (%) 31.66
NLNK's Earnings Yield (Greenblatt) (%) is ranked higher than
94% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. NLNK: 31.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NLNK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 7.4  Med: 11.50 Max: 32.76
Current: 31.66
7.4
32.76

More Statistics

Revenue(Mil) $230
EPS $ 2.43
Beta1.74
Short Percentage of Float27.89%
52-Week Range $19.75 - 58.73
Shares Outstanding(Mil)28.79

Analyst Estimate

Dec15 Dec16
Revenue(Mil)
EPS($) -1.50 -2.80
EPS without NRI($) -1.50 -2.80

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:4NX.Germany,
NewLink Genetics Corp., was incorporated in Delaware on June 4, 1999. The Company is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its products include biologic and small-molecule immunotherapy product candidates intended to treat oncology indications. Its product candidate, HyperAcute Pancreas cancer immunotherapy, or HyperAcute Pancreas, is being studied in a Phase 3 clinical trial in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment, or SPA, with the United States Food and Drug Administration, or FDA. The Company initiated this trial based on encouraging interim Phase 2 data that suggests improvement in both disease-free and overall survival. The Company has also received Fast Track and Orphan Drug designations from the FDA for this product candidate for the adjuvant treatment of surgically-resected pancreatic cancer. It has three additional product candidates in clinical development, including its HyperAcute Lung cancer immunotherapy, or HyperAcute Lung, which is being studied in a Phase 1/2 clinical trial at the National Cancer Institute, or NCI, and its HyperAcute Melanoma cancer immunotherapy, or HyperAcute Melanoma, which is being studied in an investigator-initiated Phase 2 clinical trial. To date, its HyperAcute product candidates have been dosed in more than 200 cancer patients either as a monotherapy or in combination with other therapies and have demonstrated a favorable safety profile. Its HyperAcute product candidates are based on its proprietary HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. Its HyperAcute product candidates use allogeneic (non-patient specific) cells from previously established cell lines rather than cells derived from the patient. The Company thinks its approach enables a simpler, consistent and scalable manufacturing process than therapies based on patient specific tissues or cells. Its strategy is to discover, develop and commercialize immunotherapeutic products for the treatment of cancer where the needs of patients are unmet by current therapies. The Company faces competition from other public and private biopharmaceutical companies, public and private universities and research organizations actively engaged in the discovery and research and development of products for cancer. The Company is subject to federal, state, local and foreign regulation.
» More Articles for NAS:NLNK

Headlines

Articles On GuruFocus.com
First Eagle Investment Adds to Stake in NewLink Genetics Feb 03 2016 
These Companies Show High Profit and Low Debt Jun 17 2015 
When A Stock Doubles, Don’t Trim It Automatically May 27 2015 
Greenblatt's Top Buys During First Quarter May 22 2015 
NewLink Genetics Corporation Offers a Risky Way to Generate Income Sep 11 2013 
Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse I Jun 30 2012 

More From Other Websites
NewLink Genetics to Host Its Fourth Quarter and Year End 2015 Financial Results Conference Call on... Feb 12 2016
Trade Boost From Trans-Pacific Partnership? Feb 06 2016
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Intrexon and NewLink Feb 04 2016
First Eagle Investment Adds to Stake in NewLink Genetics Feb 03 2016
NewLink Genetics says working on Zika vaccine Feb 02 2016
NewLink Genetics Corporation Announces Project to Develop New Treatment Options for the Zika Virus Feb 02 2016
NEWLINK GENETICS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 22 2016
NewLink Genetics Presents Phase 1b Data of Indoximod in Combination With Gemcitabine/Nab-Paclitaxel... Jan 22 2016
NewLink Genetics Presents Phase 1b Data of Indoximod in Combination With Gemcitabine/Nab-Paclitaxel... Jan 22 2016
NewLink Genetics Corporation to Present Phase 1b Data on Indoximod in Combination Therapy in... Jan 19 2016
NewLink Genetics Corporation to Present Phase 1b Data on Indoximod in Combination Therapy in... Jan 19 2016
NewLink Genetics Corporation Appoints Brian Wiley as Chief Commercial Officer Jan 08 2016
NewLink Genetics Corporation Appoints Brian Wiley as Chief Commercial Officer Jan 08 2016
NEWLINK GENETICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Jan 07 2016
How NewLink Genetics Corp (NLNK) Stock Stands Out in a Strong Industry Dec 28 2015
NewLink Genetics Corp. breached its 50 day moving average in a Bullish Manner : December 22, 2015 Dec 22 2015
NEWLINK GENETICS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 15 2015
NewLink Genetics Corporation Completes Enrollment of Phase 3 PILLAR Trial Evaluating Algenpantucel-L... Dec 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK